Connecting the dots: Artificial antigen presenting cell-mediated modulation of natural killer T cells

Journal of Interferon and Cytokine Research

Volumn 32, Issue 11, 2012, Pages 505-516

  Sun, Wenji ^a   Subrahmanyam, Priyanka B ^a   East, James E ^a   Webb, Tonya J ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; ANTIGEN; CD1 ANTIGEN; CD161 ANTIGEN; CD1B ANTIGEN; CD1C ANTIGEN; CD1D ANTIGEN; CD28 ANTIGEN; CD3 ANTIBODY; CD40 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; DENDRITIC CELL VACCINE; GAMMA INTERFERON; HLA A ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; MESSENGER RNA; MONOCLONAL ANTIBODY CD28; NOTCH LIGAND DELTA LIKE 1; NOTCH RECEPTOR; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; T6 ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD3+ T LYMPHOCYTE; CD34 SELECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL FUNCTION; CELL MIGRATION; CELL TRANSFORMATION; CELLULAR IMMUNITY; CHROMOSOME; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; CYTOLOGY; DENDRITIC CELL; EMBRYONIC STEM CELL; GENE EXPRESSION; GENE TRANSFER; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MEDIATOR; MELANOMA; NATURAL KILLER T CELL; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL;

ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD1D; CELL LINE, TUMOR; CYTOKINES; GALACTOSYLCERAMIDES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; NATURAL KILLER T-CELLS; NEOPLASMS;

EID: 84869021512     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2012.0045     Document Type: Review

References (88)

1. Ambrosino E, Terabe M, Halder RC, Peng J, Takaku S, Miyake S, Yamamura T, Kumar V, Berzofsky JA. 2007. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J Immunol 179(8):5126-5136.
2. Awong G, Herer E, LaMotte-Mohs RN, Zuniga-Pflucker JC. 2011. Human CD8 T cells generated in vitro from hematopoietic stem cells are functionally mature. BMC Immunol 12:22.
3. Bai L, Constantinides MG, Thomas SY, Reboulet R, Meng F, Koentgen F, Teyton L, Savage PB, Bendelac A. 2012. Distinct APCs explain the cytokine bias of alpha-galactosylceramide variants in vivo. J Immunol 188(7):3053-3061.
4. Bella SD, Gennaro M, Vaccari M, Ferraris C, Nicola S, Riva A, Clerici M, Greco M, Villa ML. (2003). Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 89(8):1463-1472. (Pubitemid 37386601)
5. Berzins SP, Smyth MJ, Baxter AG. 2011. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol 11(2):131-142.
6. Bessoles S, Fouret F, Dudal S, Besra GS, Sanchez F, Lafont V. 2008. IL-2 triggers specific signaling pathways in human NKT cells leading to the production of pro- and anti-inflammatory cytokines. J Leukoc Biol 84(1):224-233. (Pubitemid 351960298)
7. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y,Bendelac A. 1999. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 163(9):4647-4650. (Pubitemid 29501223)
8. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, Hutchinson A, Geller M, Liu N, Annable R, Shay J, Kirchhoff K, Nishi N, Ando Y, Hayashi K, Hassoun H, Steinman RM, Dhodapkar MV. 2005. Sustained expansion of NKT cells and antigen-specific T cells after injection of alphagalactosyl- ceramide loaded mature dendritic cells in cancer patients. J Exp Med 201(9):1503-1517. (Pubitemid 40664093)
9. Chang YJ, Huang JR, Tsai YC, Hung JT, Wu D, Fujio M, Wong CH, Yu AL. 2007. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids. Proc Natl Acad Sci U S A 104(25):10299-10304. (Pubitemid 47185659)
10. Courtney AN, Thapa P, Singh S, Wishahy AM, Zhou D, Sastry J. 2011. Intranasal but not intravenous delivery of the adjuvant alpha-galactosylceramide permits repeated stimulation of natural killer T cells in the lung. Eur J Immunol 41(11):3312-3322.
11. Dal Porto J, Johansen TE, Catipovic B, Parfiit DJ, Tuveson D, Gether U, Kozlowski S, Fearon DT, Schneck JP. 1993. A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. Proc Natl Acad Sci U S A 90(14):6671-6675. (Pubitemid 23207275)
12. De Libero G, Mori L. 2012. Novel insights into lipid antigen presentation. Trends Immunol 33(3):103-111.
13. de Pooter RF, Cho SK, Carlyle JR, Zuniga-Pflucker JC. 2003. In vitro generation of T lymphocytes from embryonic stem cellderived prehematopoietic progenitors. Blood 102(5):1649-1653. (Pubitemid 37022556)
14. Exley M, Porcelli S, Furman M, Garcia J, Balk S. 1998. CD161 (NKR-P1A) costimulation of CD1d-dependent activation of human T cells expressing invariant V alpha 24 J alpha Q T cell receptor alpha chains. J Exp Med 188(5):867-876. (Pubitemid 28433413)
15. Fujii S, Shimizu K, Hemmi H, Fukui M, Bonito AJ, Chen G, Franck RW, Tsuji M, Steinman RM. 2006. Glycolipid alpha-Cgalactosylceramide is a distinct inducer of dendritic cellfunction during innate and adaptive immune responses of mice. Proc Natl Acad Sci U S A 103(30):11252-11257. (Pubitemid 44156505)
16. Fujii S, Shimizu K, Klimek V, Geller MD, Nimer SD, Dhodapkar MV. 2003a. Severe and selective deficiency of interferon-gammaproducing invariant natural killer T cells in patients with myelodysplastic syndromes. Br J Haematol 122(4):617-622. (Pubitemid 36995216)
17. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. 2003b. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 198(2):267-279. (Pubitemid 36987852)
18. Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, Von Blomberg BM, Scheper RJ, Van Der Vliet HJ, Van Den Eertwegh AJ, Roelvink M, Beijnen J, Zwierzina H, Pinedo HM. 2002. A Phase I study of the natural killer T-cell ligand agalactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8(12):3702-3709. (Pubitemid 35424759)
19. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. 2004. NKT cells: what's in a name? Nat Rev Immunol 4(3):231-237. (Pubitemid 38339089)
20. Goff RD, Gao Y, Mattner J, Zhou D, Yin N, Cantu C, 3rd, Teyton L, Bendelac A, Savage PB. 2004. Effects of lipid chain lengths in alpha-galactosylceramides on cytokine release by natural killer T cells. J Am Chem Soc 126(42):13602-13603. (Pubitemid 39407224)
21. Goldberg J, Shrikant P, Mescher MF. 2003. In vivo augmentation of tumor-specific CTL responses by class I/peptide antigen complexes on microspheres (large multivalent immunogen). J Immunol 170(1):228-235. (Pubitemid 36026144)
22. Greten TF, Slansky JE, Kubota R, Soldan SS, Jaffee EM, Leist TP, Pardoll DM, Jacobson S, Schneck JP. 1998. Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19-specific CD8 + T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc Natl Acad SciU S A 95(13):7568-7573.
23. Groh V, Wu J, Yee C, Spies T. 2002. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419(6908):734-738. (Pubitemid 35177960)
24. Gumperz JE, Miyake S, Yamamura T, Brenner MB. 2002. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 195(5):625-636. (Pubitemid 34461507)
25. Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, Ritter G, Schmidt R, Harris AL, Old L, Cerundolo V. 2003. NKT cells enhance CD4+ and CD8 + T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 171(10):5140-5147. (Pubitemid 37432797)
26. Hu T, Gimferrer I, Alberola-Ila J. 2011. Control of early stages in invariant natural killer T-cell development. Immunology 134(1):1-7.
27. Hutton JF, Gargett T, Sadlon TJ, Bresatz S, Brown CY, Zola H, Shannon MF, D'Andrea RJ, Barry SC. 2009. Development of CD4 + CD25 + FoxP3 + regulatory T cells from cord blood hematopoietic progenitor cells. J Leukoc Biol 85(3):445-451.
28. Illes Z, Kondo T, Newcombe J, Oka N, Tabira T, Yamamura T. 2000. Differential expression of NK T cell V alpha 24J alpha T invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol 164(8):4375-4381. (Pubitemid 30215101)
29. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, Iizasa T, Nakayama T, Taniguchi M, Fujisawa T. 2005a. A phase I study of alpha-galactosylceramide (KRN7000)- pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 11(5):1910-1917. (Pubitemid 40471857)
30. Ishikawa E, Motohashi S, Ishikawa A, Ito T, Uchida T, Kaneko T, Tanaka Y, Horiguchi S, Okamoto Y, Fujisawa T, Tsuboi K, Taniguchi M, Matsumura A, Nakayama T. 2005b. Dendritic cell maturation by CD11c- T cells and Valpha24 + natural killer T-cell activation by alpha-galactosylceramide. Int J Cancer 117(2):265-273. (Pubitemid 41377447)
31. Kawakami K, Kinjo Y, Yara S, Koguchi Y, Uezu K, Nakayama T, Taniguchi M, Saito A. 2001. Activation of Valpha14 (+) natural killer T cells by alpha-galactosylceramide results in development of Th1 response and local host resistance in mice infected with Cryptococcus neoformans. Infect Immun 69(1):213-220. (Pubitemid 32038317)
32. Kawano T, Nakayama T, Kamada N, Kaneko Y, Harada M, Ogura N, Akutsu Y, Motohashi S, Iizasa T, Endo H, Fujisawa T, Shinkai H, Taniguchi M. 1999. Antitumor cytotoxicity mediated by ligand-activated human Va24 NKT cells. Cancer Res 59(20):5102-5105. (Pubitemid 29503967)
33. Kim CH, Johnston B, Butcher EC. 2002. Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V alpha 24 (+) V beta 11 (+) NKT cell subsets with distinct cytokine-producing capacity. Blood 100(1):11-16. (Pubitemid 35177421)
34. Kinjo Y, Wu D, Kim G, Xing GW, Poles MA, Ho DD, Tsuji M, Kawahara K, Wong CH, Kronenberg M. 2005. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434(7032):520-525. (Pubitemid 40477061)
35. Koch M, Stronge VS, Shepherd D, Gadola SD, Mathew B, Ritter G, Fersht AR, Besra GS, Schmidt RR, Jones EY, Cerundolo V. 2005. The crystal structure of human CD1d with and without alpha-galactosylceramide. Nat Immunol 6(8):819-826. (Pubitemid 43090468)
36. La Motte-Mohs RN, Herer E, Zuniga-Pflucker JC. 2005. Induction of T-cell development from human cord blood hematopoietic stem cells by Delta-like 1 in vitro. Blood 105(4): 1431-1439. (Pubitemid 40223658)
37. Larkin J, Renukaradhya GJ, Sriram V, Du W, Gervay-Hague J, Brutkiewicz RR. 2006. CD44 differentially activates mouse NK T cells and conventional T cells. J Immunol 177(1):268-279. (Pubitemid 43939138)
38. Lee PT, Benlagha K, Teyton L, Bendelac A. 2002. Distinct functional lineages of human Va24 natural killer T cells. J Exp Med 195(5):637-641. (Pubitemid 34461508)
39. Lin H, Nieda M, Hutton JF, Rozenkov V, Nicol AJ. 2006. Comparative gene expression analysis of NKT cell subpopulations. J Leukoc Biol 80(1):164-173. (Pubitemid 44835537)
40. Lu X, Song L, Metelitsa LS, Bittman R. 2006. Synthesis and evaluation of an alpha-C-galactosylceramide analogue that induces Th1-biased responses in human natural killer T cells. Chembiochem 7(11):1750-1756. (Pubitemid 44748660)
41. Macho Fernandez E, Chang J, Fontaine J, Bialecki E, Rodriguez F, Werkmeister E, Krieger V, Ehret C, Heurtault B, Fournel S, Frisch B, Betbeder D, Faveeuw C, Trottein F. 2012. Activation of invariant Natural Killer T lymphocytes in response to the alpha-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles. Int J Pharm 423(1):45-54 .
42. Maus MV, Thomas AK, Leonard DG, Allman D, Addya K, Schlienger K, Riley JL, June CH. 2002. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 20(2):143-148. (Pubitemid 34158029)
43. Miyamoto K, Miyake S, Yamamura T. 2001. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413(6855): 531-534. (Pubitemid 32938752)
44. Molling JW, Kolgen W, van der Vliet HJ, Boomsma MF, Kruizenga H, Smorenburg CH, Molenkamp BG, Langendijk JA, Leemans CR, von Blomberg BM, Scheper RJ, van den Eertwegh AJ. 2005. Peripheral blood IFN-gamma-secreting Valpha24 + Vbeta11 + NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer 116(1):87-93. (Pubitemid 40827759)
45. Moody DB, Zajonc DM, Wilson IA. 2005. Anatomy of CD1-lipid antigen complexes. Nat Rev Immunol 5(5):387-399. (Pubitemid 40685988)
46. Morgan RA, Dudley ME, Rosenberg SA. 2010. Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer J 16(4):336-341.
47. Motohashi S, Ishikawa A, Ishikawa E, Otsuji M, Iizasa T, Hanaoka H, Shimizu N, Horiguchi S, Okamoto Y, Fujii S, Taniguchi M, Fujisawa T, Nakayama T. 2006. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 12(20 Pt 1):6079-6086. (Pubitemid 44703772)
48. Nagarajan NA, Kronenberg M. 2007. Invariant NKT cells amplify the innate immune response to lipopolysaccharide. J Immunol 178(5):2706-2713. (Pubitemid 46335652)
49. Neparidze N, Dhodapkar MV. 2009. Harnessing CD1drestricted T cells toward antitumor immunity in humans. Ann N Y Acad Sci 1174:61-67.
50. Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, Ide K, Abraham R, Juji T, Macfarlane DJ, Nicol AJ. 2004. Therapeutic activation of Valpha24 + Vbeta11 + NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103(2):383-389. (Pubitemid 38140063)
51. Niemeyer M, Darmoise A, Mollenkopf HJ, Hahnke K, Hurwitz R, Besra GS, Schaible UE, Kaufmann SH. 2008. Natural killer T-cell characterization through gene expression profiling: an account of versatility bridging T helper type 1 (Th1), Th2 and Th17 immune responses. Immunology 123(1):45-56. (Pubitemid 350255998)
52. Nunez-Cruz S, Yeo WC, Rothman J, Ojha P, Bassiri H, Juntilla M, Davidson D, Veillette A, Koretzky GA, Nichols KE. 2008. Differential requirement for the SAP-Fyn interaction during NK T cell development and function. J Immunol 181(4):2311-2320.
53. Oelke M, Maus MV, Didiano D, June CH, Mackensen A, Schneck JP. 2003. Ex vivo induction and expansion of antigenspecific cytotoxic T cells by HLA-Ig-coated artificial antigenpresenting cells. Nat Med 9(5):619-625.
54. Onishi H, Morisaki T, Baba E, Kuga H, Kuroki H, Matsumoto K, Tanaka M, Katano M. 2002. Dysfunctional and short-lived subsets in monocyte-derived dendritic cells from patients with advanced cancer. Clin Immunol 105(3):286-295. (Pubitemid 36016056)
55. Paulos CM, Suhoski MM, Plesa G, Jiang T, Basu S, Golovina TN, Jiang S, Aqui NA, Powell DJ, Jr., Levine BL, Carroll RG, Riley JL, June CH. 2008. Adoptive immunotherapy: good habits instilled at youth have long-term benefits. Immunol Res 42(1- 3):182-196.
56. Pui JC, Allman D, Xu L, DeRocco S, Karnell FG, Bakkour S, Lee JY, Kadesch T, Hardy RR, Aster JC, Pear WS. 1999. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity 11(3):299-308. (Pubitemid 29463238)
57. Robey E, Chang D, Itano A, Cado D, Alexander H, Lans D, Weinmaster G, Salmon P. 1996. An activated form of Notch influences the choice between CD4 and CD8 T cell lineages. Cell 87(3):483-492. (Pubitemid 26374322)
58. Rosenberg SA, Packard BS, Aebersold PM, Dolomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA. 1988. Use of tumor-infilitrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319:1676.
59. Salvador A, Igartua M, Hernandez RM, Pedraz JL. 2012. Combination of immune stimulating adjuvants with poly(lactideco- glycolide) microspheres enhances the immune response of vaccines. Vaccine 30(3):589-596.
60. Savage AK, Constantinides MG, Han J, Picard D, Martin E, Li B, Lantz O, Bendelac A. 2008. The transcription factor PLZF directs the effector program of the NKT cell lineage. Immunity 29(3):391-403.
61. Schmitt TM, de Pooter RF, Gronski MA, Cho SK, Ohashi PS, Zuniga-Pflucker JC. 2004. Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro. Nat Immunol 5(4):410-417. (Pubitemid 38500090)
62. Schmitt TM, Zuniga-Pflucker JC. 2002. Induction of T cell development from hematopoietic progenitor cells by delta-like-1in vitro. Immunity 17(6):749-756. (Pubitemid 35477794)
63. Schofield L, Villaquiran J, Ferreira A, Schellekens H, Nussenzweig R, Nussenzweig V. 1987. Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 330(6149):664-666. (Pubitemid 18005584)
64. Schutz C, Fleck M, Mackensen A, Zoso A, Halbritter D, Schneck JP, Oelke M. 2008. Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells. Blood 111(7):3546-3552.
65. Shen C, He Y, Cheng K, Zhang D, Miao S, Zhang A, Meng F, Miao F, Zhang J. 2011. Killer artificial antigen-presenting cells deplete alloantigen-specific T cells in a murine model of alloskin transplantation. Immunol Lett 138(2):144-155.
66. Shibolet O, Alper R, Zlotogarov L, Thalenfeld B, Engelhardt D, Rabbani E, Ilan Y. 2003. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells. Int J Cancer 106(2):236-243. (Pubitemid 36835177)
67. Shimizu K, Hidaka M, Kadowaki N, Makita N, Konishi N, Fujimoto K, Uchiyama T, Kawano F, Taniguchi M, Fujii S. 2006. Evaluation of the function of human invariant NKT cells from cancer patients using alpha-galactosylceramide- loaded murine dendritic cells. J Immunol 177(5):3484-3492. (Pubitemid 44277870)
68. Shiratsuchi T, Schneck J, Kawamura A, Tsuji M. 2009. Human CD1 dimeric proteins as indispensable tools for research on CD1-binding lipids and CD1-restricted T cells. J Immunol Methods 345(1-2):49-59.
69. Steenblock ER, Fadel T, Labowsky M, Pober JS, Fahmy TM. 2011. An artificial antigen-presenting cell with paracrine delivery of IL-2 impacts the magnitude and direction of the T cell response. J Biol Chem 286(40):34883-34892.
70. Subrahmanyam PB, Webb TJ. 2012. Boosting the immune response: the use of iNKT cell ligands as vaccine adjuvants. Front Biol [Epub ahead of print]; DOI: 10.1007/s11515-012-1194-2.
71. Swann JB, Uldrich AP, van Dommelen S, Sharkey J, Murray WK, Godfrey DI, Smyth MJ. 2009. Type I natural killer T cells suppress tumors caused by p53 loss in mice. Blood 113(25):6382-6385.
72. Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, Wilson SB, Balk SP, Exley MA. 2001. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 167(7):4046-4050. (Pubitemid 32910851)
73. Terabe M, Berzofsky JA. 2008. The role of NKT cells in tumor immunity. Adv Cancer Res 101:277-348.
74. Tham EL, Jensen PL, Mescher MF. 2001. Activation of antigenspecific T cells by artificial cell constructs having immobilized multimeric peptide-class I complexes and recombinant B7-Fc proteins. J Immunol Methods 249(1-2):111-119. (Pubitemid 32171964)
75. Thapa P, Zhang G, Xia C, Gelbard A, Overwijk WW, Liu C, Hwu P, Chang DZ, Courtney A, Sastry JK, Wang PG, Li C,Zhou D. 2009. Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine 27(25-26):3484-3488.
76. Turtle CJ, Riddell SR. 2010. Artificial antigen-presenting cells for use in adoptive immunotherapy. Cancer J 16(4):374-381.
77. Tyznik AJ, Tupin E, Nagarajan NA, Her MJ, Benedict CA, Kronenberg M. 2008. Cutting edge: the mechanism of invariant NKT cell responses to viral danger signals. J Immunol 181(7):4452-4456.
78. Uchida T, Horiguchi S, Tanaka Y, Yamamoto H, Kunii N, Motohashi S, Taniguchi M, Nakayama T, Okamoto Y. 2008. Phase I study of alpha- galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol Immunother 57(3):337-345. (Pubitemid 350295376)
79. Van Coppernolle S, Verstichel G, Timmermans F, Velghe I, Vermijlen D, De Smedt M, Leclercq G, Plum J, Taghon T, Vandekerckhove B, Kerre T. 2009. Functionally mature CD4 and CD8 TCRalphabeta cells are generated in OP9-DL1 cultures from human CD34 + hematopoietic cells. J Immunol 183(8):4859-4870.
80. Velmourougane G, Raju R, Bricard G, Im JS, Besra GS, Porcelli SA, Howell AR. 2009. Synthesis and evaluation of an acyl-chain unsaturated analog of the Th2 biasing, immunostimulatory glycolipid, OCH. Bioorg Med Chem Lett 19(13):3386-3388.
81. Watarai H, Rybouchkin A, Hongo N, Nagata Y, Sakata S, Sekine E, Dashtsoodol N, Tashiro T, Fujii S, Shimizu K, Mori K, Masuda K, Kawamoto H, Koseki H, Taniguchi M. 2010. Generation of functional NKT cells in vitro from embryonic stem cells bearing rearranged invariant Valpha14-Jalpha18 TCRalpha gene. Blood 115(2):230-237.
82. Webb TJ, Bieler JG, Schneck JP, Oelke M. 2009. Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells. J Immunol Methods 346(1-2): 38-44.
83. Wu TN, Lin KH, Chang YJ, Huang JR, Cheng JY, Yu AL, Wong CH. 2011. Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy. Proc Natl Acad Sci U S A 108(42):17275-17280.
84. Yamasaki K, Horiguchi S, Kurosaki M, Kunii N, Nagato K, Hanaoka H, Shimizu N, Ueno N, Yamamoto S, Taniguchi M, Motohashi S, Nakayama T, Okamoto Y. 2011. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin Immunol 138(3):255-265.
85. Yoshimoto T, Bendelac A, Watson C, Hu-Li J, Paul WE. 1995. Role of NK1.1 + T cells in a TH2 response and in immunoglobulin E production. Science 270(5243):1845-1847.
86. Yu KO, Im JS, Molano A, Dutronc Y, Illarionov PA, Forestier C, Fujiwara N, Arias I, Miyake S, Yamamura T, Chang YT, Besra GS, Porcelli SA. 2005. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. Proc Natl Acad Sci U S A 102(9):3383-3388. (Pubitemid 40328054)
87. Zeng Z, Castano AR, Segelke BW, Stura EA, Peterson PA, Wilson IA. 1997. Crystal structure of mouse CD1: An MHC-like fold with a large hydrophobic binding groove. Science 277(5324):339-345. (Pubitemid 27450700)
88. Zhao Y, Parkhurst MR, Zheng Z, Cohen CJ, Riley JP, Gattinoni L, Restifo NP, Rosenberg SA, Morgan RA. 2007. Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. Cancer Res 67(6):2425-2429. (Pubitemid 46548926)